Others

Dishman Carbogen Amcis Ltd - Disclosure Pursuant To Regulation 30 Of SEBI (LODR) Regulations, 2015: The CompanyS Wholly Owned Subsidiary, Carbogen Amcis AGS Manufacturing Site In Hunzenschwil (Neuland), Switzerland Has Successfully Completed A US FDA Pre-Approval Inspection

| Updated on August 01, 2019 Published on August 01, 2019

We would like to inform that the Companys wholly owned subsidiary, Carbogen Amcis AGs manufacturing site in Neuland, Switzerland, has successfully completed a U.S. Food and Drug Administration (FDA) pre-approval inspection. The inspection was concluded with no Form 483s filed, thus confirming that no critical or major observation was raised during the inspection. The auditor will recommend the approval of API for which the audit was conducted.

The Hunzenschwil facility is one of Carbogen Amcis AGs four sites to offer development and manufacturing facilities for highly potent compounds. It manufactures products according to cGMP standards and is routinely inspected by Swissmedic, the FDA and external customers.

Pdf Link: Dishman Carbogen Amcis Ltd - Disclosure Pursuant To Regulation 30 Of SEBI (LODR) Regulations, 2015: The CompanyS Wholly Owned Subsidiary, Carbogen Amcis AGS Manufacturing Site In Hunzenschwil (Neuland), Switzerland Has Successfully Completed A US FDA Pre-Approval Inspection

Source : BSE - www.bseindia.com

Published on August 01, 2019
This article is closed for comments.
Please Email the Editor